SPS Members' Publication Highlight: Cross-site and cross-platform variability of automated patch clamp assessments

Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells

James Kramer, Herbert M. Himmel, Anders Lindqvist, Sonja Stoelzle-Feix, Khuram W. Chaudhary, Dingzhou Li, Georg Andrees Bohme, Matthew Bridgland-Taylor, Simon Hebeisen, Jingsong Fan, Muthukrishnan Renganathan, John Imredy, Edward S. A. Humphries, Nina Brinkwirth, Tim Strassmaier, Atsushi Ohtsuki, Timm Danker, Carlos Vanoye, Liudmila Polonchuk, Bernard Fermini, Jennifer Beck Pierson, and Gary Gintant 


Automated patch clamp (APC) instruments enable efficient evaluation of electrophysiologic effects of drugs on human cardiac currents in heterologous expression systems. Differences in experimental protocols, instruments, and dissimilar site procedures affect the variability of IC50 values characterizing drug block potency. This impacts the utility of APC platforms for assessing a drug’s cardiac safety margin. We determined variability of APC data from multiple sites that measured blocking potency of 12 blinded drugs (with different levels of proarrhythmic risk) against four human cardiac currents (hERG [IKr], hCav1.2 [L-Type ICa], peak hNav1.5, [Peak INa], late hNav1.5 [Late INa]) with recommended protocols (to minimize variance) using five APC platforms across 17 sites. IC50 variability (25/75 percentiles) differed for drugs and currents (e.g., 10.4-fold for dofetilide block of hERG current and 4-fold for mexiletine block of hNav1.5 current). Within-platform variance predominated for 4 of 12 hERG blocking drugs and 4 of 6 hNav1.5 blocking drugs. hERG and hNav1.5 block. Bland-Altman plots depicted varying agreement across APC platforms. A follow-up survey suggested multiple sources of experimental variability that could be further minimized by stricter adherence to standard protocols. Adoption of best practices would ensure less variable APC datasets and improved safety margins and proarrhythmic risk assessments.


Read the full publication here.

Recent Stories
ICH E14 and S7B: Webinar on the Recently Released Draft Q&As

Still Deciding? 4 Reasons to Attend #SPSVirtual2020

Join Us Online Aug. 27 - Chronobiology: An overview highlighting opportunities and obstacles for pharmacology